Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
LEADER Steering Committee, LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes
A positive spin on the shift is that the DTC model is more consumer-centric healthcare, where patients have greater control over their medication choices and purchasing options
Competing interest The authors declare no competing interests
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease
US$ 29.00
US$ 21.24
US$ 29.55
US$ 23.33
US$ 23.45
US$ 24.73
01443-4/asset/ec38c14e-b8b1-438c-81bb-caf4c97dc61c/main.assets/gr2.jpg)
